The MPS I market is advancing through enzyme replacement therapies and novel treatment approaches. Key players including Sanofi, Takeda, and BioMarin are developing advanced therapeutics and gene therapies that improve clinical outcomes and quality of life. Enhanced newborn screening and treatment guidelines are enabling earlier intervention and better disease management for this rare lysosomal storage disorder. Access Market Report: https://shorturl.at/nNxbj

Pheochromocytomas and Paragangliomas (PPGL) Treatment Market The PPGL market is advancing through improved diagnostic imaging and targeted therapeutic development. Key players including Progenics Pharmaceuticals, Lexicon Pharmaceuticals, and RayzeBio are developing novel radiotherapeutics and precision medicines that improve tumor control and reduce cardiovascular complications. Evolving genetic testing and treatment guidelines are enabling more personalized management approaches for these rare neuroendocrine tumors. Access Market Report:https://shorturl.at/UNpYz